(Q51648841)

8 April 2018

title

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. (English)

1 reference

8 April 2018

0 references

0 references

1

1 reference

8 April 2018

Bianca Weinstock-Guttman

17

Bianca Weinstock-Guttman

1 reference

8 April 2018

Eva Havrdova

7

0 references

Ludwig Kappos

2

Ludwig Kappos

1 reference

8 April 2018

6

Steven L Galetta

1 reference

8 April 2018

5

Gavin Giovannoni

1 reference

8 April 2018

3

Peter A Calabresi

1 reference

8 April 2018

9

David H Miller

1 reference

8 April 2018

Ernst-Wilhelm Radue

13

Ernst-Wilhelm Radue

1 reference

8 April 2018

AFFIRM and SENTINEL Investigators

21

AFFIRM and SENTINEL Investigators

1 reference

8 April 2018

Richard A Rudick

14

Richard A Rudick

1 reference

8 April 2018

Andrzej Wajgt

16

Andrzej Wajgt

1 reference

8 April 2018

Michael A Panzara

20

Michael A Panzara

1 reference

8 April 2018

author name string

Christian Confavreux

4

1 reference

8 April 2018

Fred D Lublin

8

1 reference

8 April 2018

Paul W O'Connor

10

1 reference

8 April 2018

J Theodore Phillips

11

1 reference

8 April 2018

Chris H Polman

12

1 reference

8 April 2018

William H Stuart

15

1 reference

8 April 2018

Daniel R Wynn

18

1 reference

8 April 2018

Frances Lynn

19

1 reference

8 April 2018

publication date

18 March 2009

1 reference

8 April 2018

published in

Journal of Neurology

1 reference

8 April 2018

volume

256

1 reference

8 April 2018

issue

3

1 reference

8 April 2018

page(s)

405-415

1 reference

8 April 2018

https://scigraph.springernature.com/pub.10.1007/s00415-009-0093-1

exact match

0 references

cites work

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-009-0093-1

Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.

21 January 2018

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Short-term prognosis in early relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

12 December 2020

Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

1 reference

12 December 2020

VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.

1 reference

12 December 2020

Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis

1 reference

12 December 2020

Pathogenesis of multiple sclerosis

1 reference

12 December 2020

Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Natural history of secondary-progressive multiple sclerosis

1 reference

12 December 2020

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

1 reference

12 December 2020

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

12 December 2020

Statistics in medicine--reporting of subgroup analyses in clinical trials.

1 reference

12 December 2020

Axonal pathology in multiple sclerosis: relationship to neurologic disability

1 reference

12 December 2020

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

12 December 2020

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results.

1 reference

12 December 2020

10.1007/S00415-009-0093-1

Identifiers

DOI

1 reference

8 April 2018

release_le5znucdofhz3k2scxxlz5bry4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/le5znucdofhz3k2scxxlz5bry4

24 November 2022

mapped directly with Wikidata item

1 reference

8 April 2018